Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy
- 1 February 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 6 (2), 117-129
- https://doi.org/10.1038/nrc1800
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypesNature Genetics, 2005
- Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarraysLeukemia, 2004
- Gene expression as a drug discovery toolNature Genetics, 2004
- Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemiaBlood, 2004
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- With your genes? Take one of these, three times a dayNature, 2003
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- A gene expression database for the molecular pharmacology of cancerNature Genetics, 2000
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemiaThe Journal of Pediatrics, 1991